BioCardia, Inc.

BCDA Healthcare Biotechnology

BioCardia, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $477,000.00, up 722.4% from fiscal 2024. In the quarter to June 2026, EPS grew 67.5% and free cash flow fell 5.15%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.

0.92 0.02 −2.13%
Market cap
$14.2M
P/E
0.0×
Fwd P/E
−1.7×
Dividend yield
—
F-score
4/9
Altman Z
−74.83
Beneish M
n/a
Dividend safety
n/a
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
P/E ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Piotroski F-Score
4 3 2 3 5 5 4 4 3 3
Altman Z-Score
(74.83) (65.93) (83.06) (18.91) (9.62) (3.23) 15.56 (14.78) 12.80 39.58
P/S ratio
19.47 13.98 29.31 28.46 32.35 241.57 29.27 73.72 221.58 186.58
P/FCF ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z″-Score (non-manufacturers)
(176.15) (153.77) (197.36) (51.06) (25.98) (10.71) 33.98 (53.37) (13.44) 9.30
P/Operating CF
(3.34) (2.46) (7.55) (12.84) (11.04) (10.25) (6.38) (14.19) (42.03) (42.73)
Beneish M-Score
— — (6.09) (2.80) 2.96 20.41 0.11 (5.04) — —
P/B ratio
9.31 7.15 0.00 7.86 3.17 1.83 8.77 12.15 9.54 5.22
Price to Tangible BV
9.31 7.15 0.00 7.86 3.17 1.83 8.77 12.15 9.54 5.22
EV/Sales
27.42 22.21 39.36 27.37 25.48 134.60 30.26 74.22 206.93 159.36
EV/EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EV/Operating CF
(1.58) (1.21) (1.88) (3.50) (2.49) (1.58) (2.27) (4.19) (11.43) (16.62)
EV/FCF
(1.58) (1.20) (1.88) (3.48) (2.47) (1.58) (2.24) (4.17) (11.25) (16.01)
Quick Ratio
1.03 1.02 0.32 2.11 3.51 5.24 1.43 2.21 5.48 14.84
Current Ratio
1.12 1.13 0.40 2.19 3.63 5.33 1.59 2.44 5.71 15.18
Net Debt/EBITDA
0.30 0.30 0.10 0.62 1.02 1.38 0.40 0.38 1.03 2.82
Debt/Assets
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt/Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Asset Turnover
0.13 0.02 0.07 0.11 0.05 0.01 0.10 0.06 0.03 0.04
Operating CF/Net income
0.90 0.99 0.86 0.89 0.82 0.82 0.64 0.79 0.70 0.54
Capex/Depreciation
(0.29) (0.09) (0.14) (0.85) (1.93) (0.47) (1.32) (0.75) (1.74) 0.00
Interest Coverage
— — — — (1,403.33) (5,176.33) (126.90) (119.51) (130.58) (4.38)
ROE
(950.12%) 2,074.67% (703.62%) (155.98%) (85.43%) (139.27%) (477.41%) (187.53%) (77.64%) 71.37%
ROA
(230.57%) (236.81%) (181.08%) (93.35%) (64.50%) (96.48%) (208.71%) (140.19%) (69.11%) (76.53%)
ROIC
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(2,603.80%) (2,379.04%) 563.61% (267.63%) (126.85%) (80.86%) (575.47%) (366.63%) (110.37%) (50.09%)
Average Days of Receivables
15.30 0.00 48.21 54.26 52.86 2,139.66 75.57 160.02 72.39 46.89
Research and Development Expense of Revenue
1,040.25% 7,563.79% 1,619.71% 653.40% 843.15% 6,764.83% 1,205.92% 1,352.48% 1,210.65% 578.13%
Selling, General and Administrative Expense of Revenue
695.18% 6,331.03% 921.38% 326.85% 501.18% 4,042.07% 845.49% 921.12% 1,335.07% 713.19%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
90.15% 1,277.59% 215.93% 87.50% 163.65% 2,035.86% 383.38% 443.84% 565.14% 163.54%
Graham Net Nets
0.03 (0.04) (0.22) 0.08 0.25 0.53 0.05 0.08 0.10 0.19
Graham Number
0.00 0.00 14.51 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Earnings Yield
(103.20%) (141.71%) (83.29%) (30.40%) (38.64%) (45.93%) (75.31%) (30.36%) (11.60%) (9.59%)
Free Cash Flow Yield
(89.32%) (131.94%) (71.44%) (27.63%) (31.92%) (35.37%) (46.15%) (24.17%) (8.30%) (5.33%)
Revenue per Share
0.07 0.02 0.34 1.14 0.90 0.21 1.89 2.20 1.69 9.29
Operating CF per Share
(1.12) (2.87) (7.06) (8.93) (9.19) (18.31) (25.09) (38.92) (30.66) (89.06)
Capex per Share
0.00 0.00 (0.01) (0.06) (0.10) (0.05) (0.39) (0.23) (0.48) 0.00
Free Cash Flow per Share
(1.12) (2.88) (7.07) (8.99) (9.29) (18.36) (25.47) (39.15) (31.14) (89.06)
Cash per Share
0.37 0.86 0.78 6.23 11.41 31.72 14.83 18.84 44.87 344.39
Shareholders Equity per Share
0.13 0.31 (1.14) 4.14 9.19 28.41 6.29 13.33 39.34 331.97
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
0.13 0.31 (1.14) 4.14 9.19 28.41 6.29 13.33 39.34 331.97
Free Cash Flow
(7.44) (7.89) (9.99) (10.63) (10.48) (12.39) (9.59) (11.13) (8.81) (5.52)
Working Capital
0.30 0.30 (2.15) 4.28 9.77 18.41 2.38 3.67 10.98 20.47
Capital Expenditures
(0.01) (0.01) (0.01) (0.07) (0.12) (0.03) (0.15) (0.07) (0.14) —
Net Current Asset Value
0.21 (0.26) (3.13) 2.96 8.14 18.41 1.07 3.59 10.90 20.42
EV/EBIT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capex to Sales
0.01 0.10 0.03 0.05 0.11 0.22 0.21 0.11 0.28 0.00
Price to Operating Income
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other line items
Depreciation/Fixed assets
1.50 2.03 0.89 0.48 0.33 0.47 0.61 0.61 0.46 0.35
Cash ROIC
(219.49%) (246.01%) 1,997.20% (86.75%) (45.09%) (30.53%) (120.57%) (121.69%) (36.98%) (13.17%)
Accounts Receivable Turnover
11.49 0.00 3.61 7.77 2.04 0.29 3.37 3.39 5.67 6.36
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.43 0.63 0.97 1.40
Inventory Turnover
— — — 0.00 0.00 1.00 4.94 3.11 4.23 1.67
Average Days of Payables
0.00 0.00 0.00 0.00 0.00 68,072.50 931.87 524.56 477.14 256.87
Days of Inventory on Hand
— — — 0.00 0.00 0.00 4.08 99.55 101.04 66.05
Average Receivables
0.04 — 0.13 0.17 0.50 0.50 0.21 0.18 0.08 0.09
Average Payables
0.51 0.64 0.79 0.60 0.63 0.83 0.83 0.82 0.71 0.53
Average Inventory
— — — — — 0.00 0.07 0.17 0.16 0.45
Average Assets
3.57 3.36 6.39 12.76 19.57 15.55 7.05 9.98 17.81 13.47
Average Common Equity
0.87 (0.38) 1.64 7.63 14.78 10.77 3.08 7.46 15.85 (14.44)

Fold the line items

Columns are period end dates